赖苯普利 T27827

Product Introduction
Bioactivity


英文名: Libenzapril

描述: Libenzapril (CGS 16617)是一种有效的血管紧张素转换酶抑制剂，可用于研究心肌损伤。

体内活性: The effect of intravenous (i.v.) libenzapril was studied in six healthy males by administering i.v. angiotensin I (AI) was administered in stepwise increments of 20 ng/kg/5 min until the subjects' systolic blood pressure (SBP) had increased 20-30 mm Hg above baseline. The mean baseline infusion of 63 ng/kg/5 min resulted in a significant (P < 0.05) increase in the ratio of AII to AI plasma levels from 0.52 +/- 0.46 to 7.92 +/- 4.48 and a SBP increase of 120 +/- 7.1 to 147 +/- 5.6. Within 15 minutes of starting the 1-mg infusion of libenzapril over 1.5 hours, the AII/AI ratio decreased to baseline values, and the SBP returned to baseline in 1 hour. Repeat AI challenges at 3.5 and 5 hours postdose did not increase SBP significantly. Even the 6.5-hour challenge demonstrated only a slight increase in SBP, with an AII/AI ratio of 0.26. At 24 hours, SBP was only 40% of the baseline response, demonstrating that libenzapril is a potent long-acting ACE inhibitor.[1]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : < 1mg/ml (insoluble）


关键字: CGS-16617 | Libenzapril | CGS16617

相关产品: L-Isoleucyl-L-arginine | Rentiapril racemate | Garcinone B | Vicenin-1 | Ovotransferrin (328-332) | H-Ile-Pro-Pro-OH acetate | Tuna AI acetate | Temocaprilat | Isocrenatoside | Trandolapril

相关库: Bioactive Compounds Library Max | Inhibitor Library | Bioactive Compound Library

赖苯普利 T27827信息由TargetMol中国为您提供，如您想了解更多关于赖苯普利 T27827报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途